Literature DB >> 9361271

A coherent nomenclature for Eph receptors and their ligands.

G Lemke1.   

Abstract

Mesh：

Substances：

Year:  1997        PMID： 9361271     DOI： 10.1006/mcne.1997.0630

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN： 1044-7431            Impact factor:   4.314


× No keyword cloud information.
  8 in total

1.  EphB2/R-Ras signaling regulates glioma cell adhesion, growth, and invasion.

Authors:  Mitsutoshi Nakada; Jared A Niska; Nhan L Tran; Wendy S McDonough; Michael E Berens
Journal:  Am J Pathol       Date:  2005-08       Impact factor: 4.307

2.  Expression and activation of ephexin is altered after spinal cord injury.

Authors:  Odrick R Rosas; Johnny D Figueroa; Aranza I Torrado; Mónica Rivera; José M Santiago; Franchesca Konig-Toro; Jorge D Miranda
Journal:  Dev Neurobiol       Date:  2011-07       Impact factor: 3.964

Review 3.  Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer.

Authors:  Michael S Kinch; Kelly Carles-Kinch
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

4.  EphA5-EphrinA5 interactions within the ventromedial hypothalamus influence counterregulatory hormone release and local glutamine/glutamate balance during hypoglycemia.

Authors:  Barbara Szepietowska; Wanling Zhu; Jan Czyzyk; Tore Eid; Robert S Sherwin
Journal:  Diabetes       Date:  2012-12-28       Impact factor: 9.461

5.  Low EphA7 Expression Correlated with Lymph Node Metastasis and Poor Prognosis of Patients with Esophageal Squamous Cell Carcinoma.

Authors:  Yu-Qin Bai; Jun-Yi Zhang; Chun-Ying Bai; Xiu-E Xu; Jian-Yi Wu; Bo Chen; Zhi-Yong Wu; Shao-Hong Wang; Jian Shen; Jin-Hui Shen; Xiao-Dong Yao; Lian-Zhu Gao; Bao Wu; Hong-Li Gu; Xiao-Hui Liu; Xin Li; En-Min Li; Li-Yan Xu
Journal:  Acta Histochem Cytochem       Date:  2015-06-25       Impact factor: 1.938

6.  High expression of erythropoietin-producing hepatoma cell line-B2 (EphB2) predicts the efficiency of the Qingyihuaji formula treatment in pancreatic cancer CFPAC-1 cells through the EphrinB1-EphB2 pathway.

Authors:  Yong-Qiang Hua; Zhen Chen; Zhi-Qiang Meng; Hao Chen; Jian-Gang Shen; Kun Wang; Wang Peng; Ye-Hua Shen; Lu-Ming Liu
Journal:  Oncol Lett       Date:  2014-05-12       Impact factor: 2.967

7.  Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist.

Authors:  Cassandra L Pegg; Leanne T Cooper; Jing Zhao; Michael Gerometta; Fiona M Smith; Michael Yeh; Perry F Bartlett; Jeffrey J Gorman; Andrew W Boyd
Journal:  Sci Rep       Date:  2017-07-26       Impact factor: 4.379

8.  Increased expression of EphA7 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients.

Authors:  Lin-Fang Wang; Emmanouil Fokas; Janko Juricko; An You; Frank Rose; Axel Pagenstecher; Rita Engenhart-Cabillic; Han-Xiang An
Journal:  BMC Cancer       Date:  2008-03-25       Impact factor: 4.430
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.